Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Milveterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.98 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Milveterol SCHEMBL2014099 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL2953766 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL2014100 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL2014102 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL2953768 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL168972 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL185356 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL265694 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL4385046 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL29448200 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007500233-A | — | — | 2007-01-11 | — | — | JP | claimed |
| EP-1641744-A2 | CRYSTALLINE FORM OF B2 ADRENERGIC RECEPTOR AGONIST | Theravance, Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| US-20050075271-A1 | Crystalline beta2 adrenergic receptor agonist | THERAVANCE, INC. | 2005-04-07 | — | — | US | claimed |
| WO-2004106279-A2 | CRYSTALLINE FORM OF β2 ADRENERGIC RECEPTOR AGONIST | THERAVANCE, INC. (US) | 2004-12-09 | — | — | WO | claimed |
| US-20040248985-A1 | Crystalline form of beta2 adrenergic receptor agonist | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-12-09 | — | — | US | claimed |
| US-7772434-B2 | Crystalline form of a β2 adrenergic receptor agonist | THERAVANCE, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100125150-A1 | CRYSTALLINE FORM OF A BETA2 ADRENERGIC RECEPTOR AGONIST | THERAVANCE, INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-7557247-B2 | Crystalline form of β2 adrenergic receptor agonist | THERAVANCE, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20070155990-A1 | Crystalline form of beta2 adrenergic receptor agonist | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-07-05 | — | — | US | disclosed |
| EP-1532104-A1 | CRYSTALLINE BETA-2 ADRENERGIC RECEPTOR AGONIST | Theravance, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20050075271-A1 | Crystalline beta2 adrenergic receptor agonist | THERAVANCE, INC. | 2005-04-07 | — | — | US | disclosed |
| US-20040248985-A1 | Crystalline form of beta2 adrenergic receptor agonist | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-12-09 | — | — | US | disclosed |
| WO-2004011416-A1 | CRYSTALLINE β2 ADRENERGIC RECEPTOR AGONIST | THERAVANCE, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248985-A1 | Crystalline form of beta2 adrenergic receptor agonist | ADRB2, ADRA2C, ADRA2A | ADRB2 1/4885ADRB1 4/4885ADRB3 6/4885 |
| US-20100125150-A1 | CRYSTALLINE FORM OF A BETA2 ADRENERGIC RECEPTOR AGONIST | ADRB2, ADRA2C, ADRA2A | ADRB2 1/4885ADRB1 4/4885ADRB3 7/4885 |
| US-20070155990-A1 | Crystalline form of beta2 adrenergic receptor agonist | ADRB2, ADRA2C, ADRA2A | ADRB2 1/4885ADRB1 4/4885ADRB3 6/4885 |
| US-20050075271-A1 | Crystalline beta2 adrenergic receptor agonist | ADRB2, ADRA2C, ADRA2A | ADRB2 1/4885ADRB1 4/4885ADRB3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.